Angiogenesis inhibitors for the treatment of chronic autoimmune inflammatory arthritis

Current Opinion in Investigational Drugs

Volumn 10, Issue 5, 2009, Pages 425-433

  Schoettler, N ^a   Brahn, E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; ANGIOSTATIN; AXITINIB; BEVACIZUMAB; ENDOSTATIN; FAS LIGAND; FIBROBLAST GROWTH FACTOR; FUMAGILLOL CHLOROACETYLCARBAMATE; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE INHIBITOR; MEDI 552; PACLITAXEL; PEGAPTANIB; PENTOXIFYLLINE; PPI 2458; RANIBIZUMAB; ROMIDEPSIN; SERINE PROTEINASE INHIBITOR; SORAFENIB; STAT3 PROTEIN; SUNITINIB; THALIDOMIDE; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VATALANIB;

ANTIANGIOGENIC ACTIVITY; ARTHRITIS; AUTOIMMUNE DISEASE; CELL HYPERPLASIA; CELL PROLIFERATION; CHRONIC ARTHRITIS; CLINICAL TRIAL; COLORECTAL CANCER; DRUG WITHDRAWAL; ENDOTHELIUM CELL; ERYTHEMA NODOSUM LEPROSUM; HUMAN; KIDNEY CANCER; LUNG CANCER; MICROTUBULE ASSEMBLY; NEOPLASM; PANCREAS CANCER; PANNUS; RETINOPATHY; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; ARTHRITIS, RHEUMATOID; CHRONIC DISEASE; HUMANS; INFLAMMATION MEDIATORS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 67649344520     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 350(23):2335-2342.
2. Ip MS, Scott IU, Brown GC, Brown MM, Ho AC, Huang SS, Recchia FM, American Academy of Ophthalmology: Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: A report by the American Academy of Ophthalmology. Ophthalmology (2008) 115(10):1837- 1846.
3. Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, Jackman RW, Senger DR, Dvorak HF, Brown LF: Vascular permeability factor/endothelial growth factor (VPF/VEGF): Accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med (1994) 180(1):341- 346.
4. Nagashima M, Asano G, Yoshino S: Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis. J Rheumatol (2000) 27(10):2339-2342.
5. Peters CL, Morris CJ, Mapp PI, Blake DR, Lewis CE, Winrow VR: The transcription factors hypoxia-inducible factor 1a and Ets-1 colocalize in the hypoxic synovium of inflamed joints in adjuvant-induced arthritis. Arthritis Rheum (2004) 50(1):291-296.
6. Athanasou NA, Quinn J, Heryet A, Puddle B, Woods CG, McGee JO: The immunohistology of synovial lining cells in normal and inflamed synovium. J Pathol (1988) 155(2):133-142.
7. Malone DG, Wahl SM, Tsokos M, Cattell H, Decker JL, Wilder RL: Immune function in severe, active rheumatoid arthritis. A relationship between peripheral blood mononuclear cell proliferation to soluble antigens and synovial tissue immunohistologic characteristics. J Clin Invest (1984) 74(4):1173-1185.
8. Bromley M, Bertfield H, Evanson JM, Woolley DE: Bidirectional erosion of cartilage in the rheumatoid knee joint. Ann Rheum Dis (1985) 44(10):676-681.
9. Hitchon CA, El-Gabalawy HS, Bezabeh T: Characterization of synovial tissue from arthritis patients: A proton magnetic resonance spectroscopic investigation. Rheumatol Int (2009):doi:10.1007/s00296-009-0865-z.
10. Lainer-Carr D, Brahn E: Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis. Nat Clin Pract Rheumatol (2007) 3(8):434-442.
11. Koch AE, Distler O: Vasculopathy and disordered angiogenesis in selected rheumatic diseases: Rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther (2007) 9(Suppl 2):S3.
12. Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O: Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med (2003) 47(3):149-161.
13. Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong WL, Pope RM, Ferrara N: Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol (1994) 152(8):4149-4156.
14. Veikkola T, Alitalo K: VEGFs, receptors and angiogenesis. Semin Cancer Biol (1999) 9(3):211-220.
15. Ikeda M, Hosoda Y, Hirose S, Okada Y, Ikeda E: Expression of vascular endothelial growth factor isoforms and their receptors Flt-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis. J Pathol (2000) 191(4):426-433.
16. Bottomley MJ, Webb NJ, Watson CJ, Holt PJ, Freemont AJ, Brenchley PE: Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): Specific upregulation by tumor necrosis factor- (TNFα) in synovial fluid. Clin Exp Immunol (1999) 117(1):171-176.
17. Berse B, Hunt JA, Diegel RJ, Morganelli P, Yeo K, Brown F, Fava RA: Hypoxia augments cytokine (transforming growth factor- (TGFβ) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin Exp Immunol (1999) 115(1):176-182.
18. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL: Dimerization, DNA binding, and transactivation properties of hypoxia- inducible factor 1. J Biol Chem (1996) 271(30):17771-17778.
19. Liu LX, Lu H, Luo Y, Date T, Belanger AJ, Vincent KA, Akita GY, Goldberg M, Cheng SH, Gregory RJ, Jiang C: Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1. Biochem Biophys Res Commun (2002) 291(4):908-914.
20. Giatromanolaki A, Sivridis E, Maltezos E, Athanassou N, Papazoglou D, Gatter KC, Harris AL, Koukourakis MI: Upregulated hypoxia inducible factor-1α and -2α pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res Ther (2003) 5(4):R193-R201.
21. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ et al: Angiopoietin-2, a natural antagonist for TIE2 that disrupts in vivo angiogenesis. Science (1997) 277(5322): 55-60.
22. Shahrara S, Volin MV, Connors MA, Haines GK, Koch AE: Differential expression of the angiogenic TIE receptor family in arthritic and normal synovial tissue. Arthritis Res (2002) 4(3):201-208.
23. Yuan HT, Venkatesha S, Chan B, Deutsch U, Mammoto T, Sukhatme VP, Woolf AS, Karumanchi SA: Activation of the orphan endothelial receptor TIE1 modifies TIE2-mediated intracellular signaling and cell survival. FASEB J (2007) 21(12):3171-3183.
24. Adams JD, Flora KP, Goldspiel BR, Wilson JW, Arbuck SG, Finley R: Taxol: A history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst Monogr (1993) (15):141-147.
25. Kielbassa K, Schmitz C, Gerke V: Disruption of endothelial microfilaments selectively reduces the transendothelial migration of monocytes. Exp Cell Res (1998) 243(1):129-141.
26. Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM: The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA (1997) 94(12):6099-6103.
27. Johnson BA, Haines GK, Harlow LA, Koch AE: Adhesion molecule expression in human synovial tissue. Arthritis Rheum (1993) 36(2):137-146.
28. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 79(7):1157-1164.
29. 3 for angiogenesis. Science (1994) 264(5158):569-571.
30. Strasser A, Jost PJ, Nagata S: The many roles of Fas receptor signaling in the immune system. Immunity (2009) 30(2):180-192.
31. Kim WU, Kwok SK, Hong KH, Yoo SA, Kong JS, Choe J, Cho CS: Soluble Fas ligand inhibits angiogenesis in rheumatoid arthritis. Arthritis Res Ther (2007) 9(2):R42.
32. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E et al: VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA (2002) 99(17):11393-11398.
33. 165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem (1998) 273(32):20556-20567.
34. Grosios K, Wood J, Esser R, Raychaudhuri A, Dawson J: Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK-787/ZK-222584, causes significant anti-arthritic effects in models of rheumatoid arthritis. Inflamm Res (2004) 53(4):133-142.
35. De Bandt M, Ben Mahdi MH, Ollivier V, Grossin M, Dupuis M, Gaudry M, Bohlen P, Lipson KE, Rice A, Wu Y, Gougerot-Pocidalo MA, Pasquier C: Blockade of vascular endothelial growth factor receptor I (VEGFR-I), but not VEGFR-II, suppresses joint destruction in the K/BxN model of rheumatoid arthritis. J Immunol (2003) 171(9):4853-4859.
36. Mould AW, Scotney P, Greco SA, Hayward NK, Nash A, Kay GF: Prophylactic but not therapeutic activity of a monoclonal antibody that neutralizes the binding of VEGFB to VEGFR1 in a murine collagen-induced arthritis model. Rheumatology (Oxford) (2008) 47(3):263-266.
37. Jin P, Zhang J, Sumariwalla PF, Ni I, Jorgensen B, Crawford D, Phillips S, Feldmann M, Shepard HM, Paleolog EM: Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis. Arthritis Res Ther (2008) 10(4):R73.
38. Sasakawa Y, Naoe Y, Noto T, Inoue T, Sasakawa T, Matsuo M, Manda T, Mutoh S: Antitumor efficacy of FK-228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem Pharmacol (2003) 66(6):897-906.
39. Manabe H, Nasu Y, Komiyama T, Furumatsu T, Kitamura A, Miyazawa S, Ninomiya Y, Ozaki T, Asahara H, Nishida K: Inhibition of histone deacetylase down-regulates the expression of hypoxia-induced vascular endothelial growth factor by rheumatoid synovial fibroblasts. Inflamm Res (2008) 57(1):4-10.
40. Chen Y, Donnelly E, Kobayashi H, Debusk LM, Lin PC: Gene therapy targeting the TIE2 function ameliorates collagen-induced arthritis and protects against bone destruction. Arthritis Rheum (2005) 52(5):1585- 1594.
41. Issekutz AC, Sapru K: Modulation of adjuvant arthritis in the rat by 2-methoxyestradiol: An effect independent of an anti-angiogenic action. Int Immunopharmacol (2008) 8(5):708-716.
42. Brahn E, Banquerigo ML, Lee JK, Park EJ, Fogler WE, Plum SM: An angiogenesis inhibitor, 2-methoxyestradiol, involutes rat collagen-induced arthritis and suppresses gene expression of synovial vascular endothelial growth factor and basic fibroblast growth factor. J Rheumatol (2008) 35(11):2119-2128.
43. EntreMed Inc: EntreMed Focuses on development of ENMD-2076. Press Release (2008): December 15.
44. Kurose A, Yoshida W, Yoshida M, Sawai T: Effects of paclitaxel on cultured synovial cells from patients with rheumatoid arthritis. Cytometry (2001) 44(4):349-354.
45. Brahn E, Tang C, Banquerigo ML: Regression of collagen-induced arthritis with taxol, a microtubule stabilizer. Arthritis Rheum (1994) 37(6):839-845.
46. Oliver SJ, Banquerigo ML, Brahn E: Suppression of collagen- induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. Cell Immunol (1994) 157(1):291-299.
47. Liggins RT, Cruz T, Min W, Liang L, Hunter WL, Burt HM: Intra-articular treatment of arthritis with microsphere formulations of paclitaxel: Biocompatibility and efficacy determinations in rabbits. Inflamm Res (2004) 53(8):363-372.
48. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 88(2):277-285.
49. Peacock DJ, Ku G, Banquerigo ML, Brahn E: Suppression of collagen arthritis with antibodies to an arthritogenic, oligoclonal T-cell line. Cell Immunol (1992) 140(2):444-452.
50. Peacock DJ, Banquerigo ML, Brahn E: Angiogenesis inhibition suppresses collagen arthritis. J Exp Med (1992) 175(4):1135-1138.
51. Logothetis CJ, Wu KK, Finn LD, Daliani D, Figg W, Ghaddar H, Gutterman JU: Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res (2001) 7(5):1198-1203.
52. de Bandt M, Grossin M, Weber AJ, Chopin M, Elbim C, Pla M, Gougerot-Pocidalo MA, Gaudry M: Suppression of arthritis and protection from bone destruction by treatment with TNP-470/AGM-1470 in a transgenic mouse model of rheumatoid arthritis. Arthritis Rheum (2000) 43(9):2056- 2063.
53. Takeda Chemical Industries Ltd: Financial results for FY2001 - Data book. Company Communication (2002): March 28.
54. Bainbridge J, Madden L, Essex D, Binks M, Malhotra R, Paleolog EM: Methionine aminopeptidase-2 blockade reduces chronic collagen-induced arthritis: Potential role for angiogenesis inhibition. Arthritis Res Ther (2007) 9(6):R127.
55. Lazarus DD, Doyle EG, Bernier SG, Rogers AB, Labenski MT, Wakefield JD, Karp RM, Clark EJ, Lorusso J, Hoyt JG, Thompson CD et al: An inhibitor of methionine aminopeptidase type-2, PPI-2458, ameliorates the pathophysiological disease processes of rheumatoid arthritis. Inflamm Res (2008) 57(1):18-27.
56. v integrins during angiogenesis: Insights into potential mechanisms of action and clinical development. J Clin Invest (1999) 103(9):1227-1230.
57. 3(vitronectin receptor) antagonist, in rat adjuvant-induced arthritis. Arthritis Rheum (2001) 44(1):128-137.
58. 3 antagonist. J Clin Invest (1999) 103(1):47-54.
59. AstraZeneca plc: AstraZeneca development pipeline: 7 December 2007. Company World Wide Web site (2007): December 07.
60. Kurosaka D, Yoshida K, Yasuda J, Yokoyama T, Kingetsu I, Yamaguchi N, Joh K, Matsushima M, Saito S, Yamada A: Inhibition of arthritis by systemic administration of endostatin in passive murine collagen-induced arthritis. Ann Rheum Dis (2003) 62(7):677-679.
61. Matsuno H, Yudoh K, Uzuki M, Nakazawa F, Sawai T, Yamaguchi N, Olsen BR, Kimura T: Treatment with the angiogenesis inhibitor endostatin: A novel therapy in rheumatoid arthritis. J Rheumatol (2002) 29(5):890-895.
62. Yue L, Wang H, Liu LH, Shen YX, Wei W: Anti-adjuvant arthritis of recombinant human endostatin in rats via inhibition of angiogenesis and proinflammatory factors. Acta Pharmacol Sin (2004) 25(9):1182-1185.
63. Kurosaka D, Yoshida K, Yasuda J, Yasuda C, Noda K, Furuya K, Ukichi T, Kingetsu I, Joh K, Yamaguchi N, Saito S, Yamada A:The effect of endostatin evaluated in an experimental animal model of collagen-induced arthritis. Scand J Rheumatol (2007) 36(6):434-441.
64. Yue L, Shen YX, Feng LJ, Chen FH, Yao HW, Liu LH, Wu Q, Wang H: Blockage of the formation of new blood vessels by recombinant human endostatin contributes to the regression of rat adjuvant arthritis. Eur J Pharmacol (2007) 567(1-2): 166-170.
65. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell (1994) 79(2):315-328.
66. Kim JM, Ho SH, Park EJ, Hahn W, Cho H, Jeong JG, Lee YW, Kim S: Angiostatin gene transfer as an effective treatment strategy in murine collagen-induced arthritis. Arthritis Rheum (2002) 46(3):793-801.
67. Takahashi H, Kato K, Miyake K, Hirai Y, Yoshino S, Shimada T: Adeno-associated virus vector-mediated anti-angiogenic gene therapy for collagen-induced arthritis in mice. Clin Exp Rheumatol (2005) 23(4):455-461.
68. Kato K, Miyake K, Igarashi T, Yoshino S, Shimada T: Human immunodeficiency virus vector-mediated intra-articular expression of angiostatin inhibits progression of collagen-induced arthritis in mice. Rheumatol Int (2005) 25(7):522-529.
69. Upton C, Macen JL, Wishart DS, McFadden G: Myxoma virus and malignant rabbit fibroma virus encode a serpin-like protein important for virus virulence. Virology (1990) 179(2):618-631.
70. Maksymowych WP, Nation N, Nash P, Macen J, Lucas A, McFadden G, Russell AS: Amelioration of antigen-induced arthritis in rabbits treated with a secreted viral serine proteinase inhibitor. J Rheumatol (1996) 23(5):878-882.
71. Richardson M, Liu L, Dunphy L, Wong D, Sun Y, Viswanathan K, Singh G, Lucas A: Viral serpin, Serp-1, inhibits endogenous angiogenesis in the chicken chorioallantoic membrane model. Cardiovasc Pathol (2007) 16(4):191-202.
72. Franks ME, Macpherson GR, Figg WD: Thalidomide. Lancet (2004) 363(9423):1802-1811.
73. D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA (1994) 91(9):4082-4085.
74. Hauschild A, Kroeger H, Mitchison NA, Ugrinovic S, Zwingenberger K: Thalidomide therapy of established collagen-induced arthritis (CIA) not accompanied by an evident Th2 shift. Clin Exp Immunol (1997) 108(3):428-431.
75. Oliver SJ, Cheng TP, Banquerigo ML, Brahn E: The effect of thalidomide and 2 analogs on collagen-induced arthritis. J Rheumatol (1998) 25(5):964-969.
76. Huizinga TW, Dijkmans BA, van der Velde EA, van de Pouw Kraan TC, Verweij CL, Breedveld FC: An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis. Ann Rheum Dis (1996) 55(11):833-836.
77. Gutierrez-Rodriguez O, Starusta-Bacal P, Gutierrez-Montes O: Treatment of refractory rheumatoid arthritis - The thalidomide experience. J Rheumatol (1989) 16(2):158-163.